Core Points - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit due to alleged misleading statements and failure to disclose important information during the class period from May 7, 2025, to August 5, 2025 [1] - Allegations include that LifeMD's competitive position was overstated, and that the company did not properly account for rising customer acquisition costs, particularly in its RexMD segment and for obesity treatment drugs [1] - The deadline for shareholders to register for the class action and seek lead plaintiff status is October 27, 2025 [2] Company Specifics - LifeMD, Inc. is facing allegations of materially false and misleading statements regarding its business operations and prospects, which may have led to an artificial inflation of its stock price [1] - The lawsuit highlights concerns over the company's guidance for 2025, which was deemed reckless given the unaccounted rising customer acquisition costs [1] Legal Context - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3] - Shareholders who register will be enrolled in a portfolio monitoring system to receive updates on the case [2]

Core Insights - LifeMD, Inc. will report its financial results for the three and nine months ended September 30, 2025, on November 6, 2025, after the U.S. financial markets close [1] - A conference call will be held on the same day at 4:30 p.m. Eastern time to discuss the results [2] Company Overview - LifeMD is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [3] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, and a state-of-the-art compounding pharmacy to enhance access to high-quality and affordable care [3]

NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=173228&from=3 CLASS PERIOD: May 7, 2025 to August ...

Renowned Menopause and Hormone Specialist to Help Guide and Represent LifeMD’s Comprehensive and Personalized Care Offering for WomenNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Tara Scott, MD, widely known as “The Hormone Guru,” as ambassador and clinical advisor for its comprehensive women’s health program. A respected physician, educator, and advocate, Dr. Scott will help champion LifeMD’s ...

NEW YORK, Oct. 21, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important October 27, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased LifeMD securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming October 27, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired LifeMD, Inc. ("LifeMD†or the "Company†) (NASDAQ: LFMD) securities between May 7, 2025 and August 5, 2025, inclusive (the "Class Period†). IF YOU ARE AN INVESTOR WHO LOST MONEY ON LIFEMD, INC. (LFMD), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAW. ...

Core Viewpoint - A federal securities fraud class action lawsuit has been filed against LifeMD, alleging misleading statements regarding its financial health and growth prospects, particularly following a significant stock price decline after its earnings report in August 2025 [1][4]. Summary by Relevant Sections Lawsuit Details - The lawsuit, titled Johnston v. LifeMD, Inc., covers the period from May 7, 2025, to August 5, 2025, claiming that LifeMD made false statements, especially on May 6, 2025, when it reported first-quarter results and raised its full-year revenue and adjusted EBITDA guidance [2]. - The complaint asserts that LifeMD's optimistic outlook regarding its competitive position in virtual obesity care and performance from its RexMD brand was misleading, as it did not disclose significant operational challenges [2][3]. Financial Performance and Stock Impact - LifeMD's stock price fell over 44% the day after the company announced its second-quarter results on August 5, 2025, which missed revenue and earnings per share estimates and included a reduction in full-year guidance [4]. - During the earnings call, management attributed the poor performance to "temporary elevated customer acquisition costs" in the RexMD business and issues with patient refunds in its weight management offerings [4]. Investor Actions - Investors who suffered losses during the specified period are encouraged to participate in the lawsuit as a means to recover damages [5]. - Hagens Berman, the law firm leading the investigation, is looking into whether LifeMD was aware of but failed to disclose key operational problems [6].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against LifeMD, Inc. (“LifeMD” or the “Company”) (NASDAQ: LFMD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether LifeMD and certain of its officers ...

Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly making materially false and misleading statements regarding its competitive position and financial guidance during the Class Period from May 7, 2025, to August 5, 2025 [3][7]. Allegation Details - The lawsuit claims that defendants overstated LifeMD's competitive position [3]. - It is alleged that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs [3]. - The lawsuit asserts that the statements made by the defendants about LifeMD's business, operations, and prospects were materially false and misleading [3]. Next Steps - Investors who purchased LifeMD shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 27, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5]. - The firm has offices in New York, California, and South Carolina and handles cases in state and federal courts across the country [5].

Core Viewpoint - A class action securities lawsuit has been filed against LifeMD, Inc. for alleged securities fraud affecting investors between May 7, 2025, and August 5, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that defendants materially overstated LifeMD's competitive position [2]. - It is alleged that defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for rising customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [2]. - As a result, the statements made by defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until October 25, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and class members may be entitled to compensation without any out-of-pocket costs [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].